TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Rein Therapeutics ( (RNTX) ).
On July 29, 2025, Rein Therapeutics entered into a Pre-Paid Advance Agreement with YA II PN, Ltd., allowing the company to request up to $6.0 million in pre-paid advances over a year. The agreement stipulates that advances will be purchased at 95% of their face value, with interest accruing at 8% annually, increasing to 18% upon default. On October 23, 2025, Rein Therapeutics received a third pre-paid advance of $1.0 million from Yorkville, with net proceeds of $0.95 million, as part of a private placement exempt from registration under the Securities Act of 1933.
The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Average Trading Volume: 139,445
Technical Sentiment Signal: Sell
Current Market Cap: $28.73M
Learn more about RNTX stock on TipRanks’ Stock Analysis page.